Candel Therapeutics (CADL) Insider Trading & Ownership $8.75 +0.81 (+10.20%) Closing price 04:00 PM EasternExtended Trading$8.73 -0.02 (-0.23%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Candel Therapeutics (NASDAQ:CADL) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage41.60%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$7.50 MNumber OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$1.22 M Get CADL Insider Trade Alerts Want to know when executives and insiders are buying or selling Candel Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CADL Insider Buying and Selling by Quarter Remove Ads Candel Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/15/2025Francesca BaroneInsiderSell13,534$7.22$97,715.48 1/15/2025Seshu TyagarajanCTOSell14,322$7.22$103,404.84 1/8/2025Francesca BaroneInsiderSell13,673$8.22$112,392.06 12/16/2024Paul B ManningDirectorBuy1,250,000$6.00$7,500,000.00 11/29/2024Seshu TyagarajanCTOSell20,392$4.56$92,987.52 11/29/2024William Garrett NicholsInsiderSell13,935$4.56$63,543.60 10/14/2024Estuardo Aguilar-CordovaMajor ShareholderSell15,000$6.02$90,300.00 10/11/2024Estuardo Aguilar-CordovaMajor ShareholderSell15,000$6.05$90,750.00 10/3/2024Estuardo Aguilar-CordovaMajor ShareholderSell1,800$6.85$12,330.00 7/17/2024Charles SchochInsiderSell9,884$6.47$63,949.48 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 7/17/2024Paul Peter TakCEOSell22,528$6.47$145,756.16 7/17/2024Seshu TyagarajanCTOSell14,851$6.47$96,085.97 7/11/2024Charles SchochInsiderSell8,897$5.97$53,115.09 7/11/2024Paul Peter TakCEOSell20,293$5.97$121,149.21 7/11/2024Seshu TyagarajanCTOSell13,330$5.97$79,580.10 (Data available from 1/1/2013 forward) CADL Insider Trading Activity - Frequently Asked Questions Who is on Candel Therapeutics's Insider Roster? The list of insiders at Candel Therapeutics includes Charles Schoch, Estuardo Aguilar-Cordova, Francesca Barone, Jason Amello, Joseph C Papa, Paul B Manning, Paul Peter Tak, Seshu Tyagarajan, and William Garrett Nichols. Learn more on insiders at CADL. What percentage of Candel Therapeutics stock is owned by insiders? 41.60% of Candel Therapeutics stock is owned by insiders. Learn more on CADL's insider holdings. Which Candel Therapeutics insiders have been buying company stock? The following insider purchased CADL shares in the last 24 months: Paul B Manning ($7,500,000.00). How much insider buying is happening at Candel Therapeutics? Insiders have purchased a total of 1,250,000 CADL shares in the last 24 months for a total of $7,500,000.00 bought. Which Candel Therapeutics insiders have been selling company stock? The following insiders have sold CADL shares in the last 24 months: Charles Schoch ($117,064.57), Estuardo Aguilar-Cordova ($193,380.00), Francesca Barone ($210,107.54), Paul Peter Tak ($266,905.37), Seshu Tyagarajan ($372,058.43), and William Garrett Nichols ($63,543.60). How much insider selling is happening at Candel Therapeutics? Insiders have sold a total of 197,439 Candel Therapeutics shares in the last 24 months for a total of $1,223,059.51 sold. Candel Therapeutics Key ExecutivesDr. Paul-Peter Tak FMEDSCI (Age 63)M.D., Ph.D., President, CEO & Director Compensation: $1.12MDr. Estuardo Aguilar-Cordova Inf. (Age 65)M.D., Ph.D., Founder & Director Compensation: $35k3 recent tradesDr. Francesca Barone M.D. (Age 46)Ph.D., Chief Scientific Officer Compensation: $506.76kMr. Charles Schoch (Age 39)Interim CFO, VP of Finance & Corporate Controller Dr. Seshu Tyagarajan Ph.D. (Age 56)Chief Technical & Development Officer Compensation: $335.27kMs. Ileen B. WinickChief People OfficerMs. Susan Stewart J.D. (Age 63)L.L.M., Chief Regulatory Officer Dr. William Garrett Nichols M.D. (Age 55)M.S., Chief Medical Officer 1 recent trades More Insider Trading Tools from MarketBeat Related Companies SPRY Insider Buying ETNB Insider Buying NRIX Insider Buying VIR Insider Buying ADPT Insider Buying ELVN Insider Buying RCUS Insider Buying NTLA Insider Buying GYRE Insider Buying XNCR Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles SentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It MattersInsider Scoop: 4 Stocks Insiders Are Buying and Selling2 Stocks Insiders Are Buying and 1 They're Selling3 Stocks With Robust Growth Outlooks Insiders Are Buying This page (NASDAQ:CADL) was last updated on 3/14/2025 by MarketBeat.com Staff From Our PartnersTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredOur #1 Defense Stock for MarchChina just deepened its military alliance with America's enemies in the Middle East... By conducting joint ...Behind the Markets | SponsoredElon’s desperate gambleWarning: "DOGE Collapse" Imminent After months of cost-cutting, controversy, and media buzz, DOGE is on the...Altimetry | SponsoredTrump’s new tariffs could break China’s grip on manufacturingLooming trade wars have China scrambling… Over 90% of global corporate executives said they are shutting do...Weiss Ratings | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
